Organization
HiberCell
5 clinical trials
2 abstracts
Clinical trial
A Multicenter, Open-label, Phase 1a/b Study of HC-7366 in Subjects With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2024-02-09
Clinical trial
A Multicenter, Open-label, Phase 1a Study of HC-5404-FU in Subjects With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-12-07
Clinical trial
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced (Inoperable) or Metastatic Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line ChemoStatus: Terminated, Estimated PCD: 2024-03-04
Clinical trial
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal TherapyStatus: Completed, Estimated PCD: 2023-03-22
Abstract
A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.Org: Hospital of the University of Pennsylvania, Hunstman Cancer Institute at the University of Utah, University of Utah, Memorial Sloan Kettering Cancer Center, Celldex Therapeutics,
Abstract
A RANDOMIZED CONTROLLED TRIAL OF THE UTILITY OF ULTRASONOGRAPHY TO GUIDE LOCAL STEROID INJECTION IN THE PAINFUL SHOULDER Org: DalCor Pharmaceuticals, CHUV, Lausanne, Switzerland, HiberCell, Estavayer-le-lac,